Global Interest is High for Biostar’s Stem Cell Treatment of Parkinson’s Disease
-Biostar StemCell Research Institute’s stem cell treatm
Read moreNews
-
2024-05-21
-
-
2017-05-02
Prominent Mountaineer, Hong-gil Um,, Was Appointed as Biostar’s PR Ambassador for ‘Joint Stem’,— a Stem Cell-Based Medicine for Treating Degenerative Arthritis
On May 2, 2017, Biostar Stem Cell Research Institute (CEO- Jeong-chan Ra), co-operated by Nature Cell and R-Bio, appointed Hong-gil Um, a renowned South Korean mountaineer, as an honorary ambassador to promote ‘JointStem,’ an autologous stem cell-based medicine for treating degenerative arthritis.
Read more-
-
2017-04-14
NATURE CELL Selects an Additional U.S. Clinical Center for Trials of ‘AstroStem,’ a Stem Cell Drug for Alzheimer’s Disease
Biostar Stem Cell Research Institute , which is co-operated by NATURE CELL and R-bio, published that a third clinical center for the phases 1 and 2 of ‘AstroStem’, a stem cell drug for Alzheimer’s disease that is currently undergoing clinical trials following the approval from the U.S. FDA, has been additionally selected.
Read more-
-
2017-03-09
Nature Cell started Commercial Clinical Trials Phase Ⅰ and Ⅱ ‘ASTROSTEM,’ Stem Cell Drug for Alzheimer disease treatment in U.S.
SEOUL, South Korea – Bio technology enterprise Nature Cell (KOSDAQ: 007390) announced that it had started to recruit patients for its clinical trials of ‘ASTROSTEM,’ an stem cell drug for Alzheimer disease treatment, in the U.S.
Read more-
-
2017-02-14
South Korea’s Autologous Fat Stem-cell Culture Technology Spearheads Japan’s Regenerative Medical Technology
According to the Regenerative Medical Act of Japan, which has been enforced since November 25, 2015, R-Japan, an affiliated with Nature Cell, got permission of Type 2 Specific Cell Artifact (stem-cell) from Japan’s Ministry of Health, Labor and Welfare, which is the only case among South Korean companies; R-Japan announced its business performance for 2016.
Read more-
-
2017-02-10
R-Bio’s VASCOSTEM has been registered with KFDA as the Orphan Drug in Development Phase.
The stem cell treatment VASCOSTEM has been registered as the Orphan Drug in Development Phase.
Read more-
Biostar Stem Cell Research Institute
08506
305, Lotte IT Castle Building #2, 550-1, Gasan-dong, Geumcheon-gu, Seoul
R Bio Co.,Ltd.
+82 -2-858-8021~5
© Copyright 2024 Biostar stem cell Research and Development All rights reserved
Most Commented